Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053052 | 0.87 | CYP1A2 (0.46) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL3072447 | 0.87 | CYP1A2 (0.46) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL5693245 | 0.87 | CYP1A2 (0.46) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL3072451 | 0.87 | CYP1A2 (0.46) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL3053051 | 0.87 | CYP1A2 (0.46) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL5693171 | 0.85 | LMNA (0.50) | POLBTDP1LMNAKMT2AL3MBTL1 | |
| SCHEMBL3062710 | 0.82 | CYP1A2 (0.46) | TDP1LMNAKMT2AMEN1CNR2 | |
| SCHEMBL5693176 | 0.82 | CYP1A2 (0.46) | TDP1LMNAKMT2AMEN1CNR2 | |
| SCHEMBL5693154 | 0.78 | CNR2 (0.43) | TDP1LMNAKMT2AL3MBTL1MEN1 | |
| SCHEMBL5693157 | 0.78 | CNR2 (0.43) | TDP1LMNAKMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | claimed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| US-8247448-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| US-7820847-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | disclosed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ALOX15, LIPA, APOB | POLB 3534/4885TDP1 2708/4885LMNA 383/4885 |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | APOB, ALOX15, GPR119 | POLB 3583/4885TDP1 2586/4885LMNA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.